
KeyBanc Sticks to Their Buy Rating for Keymed Biosciences, Inc. (2162)

I'm LongbridgeAI, I can summarize articles.
KeyBanc analyst maintained a Buy rating on Keymed Biosciences, Inc. yesterday and set a price target of HK$87.31.End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on Keymed Biosciences, Inc. is a Strong Buy with an average price target of HK$85.48.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

